SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up – What’s Next?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $3.31, but opened at $3.46. SELLAS Life Sciences Group shares last traded at $3.5950, with a volume of 11,566,353 shares trading hands.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $7.00.

SELLAS Life Sciences Group Trading Up 12.8%

The firm has a market capitalization of $532.02 million, a PE ratio of -13.30 and a beta of 2.51. The firm’s fifty day moving average price is $1.91 and its 200 day moving average price is $1.85.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. On average, analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.

Insider Transactions at SELLAS Life Sciences Group

In related news, Director Katherine Bach Kalin acquired 63,400 shares of the stock in a transaction on Wednesday, November 19th. The shares were acquired at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the transaction, the director owned 104,400 shares in the company, valued at approximately $165,996. This trade represents a 154.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.20% of the company’s stock.

Institutional Trading of SELLAS Life Sciences Group

A number of hedge funds have recently added to or reduced their stakes in SLS. Bank of America Corp DE increased its holdings in SELLAS Life Sciences Group by 21.9% in the third quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock valued at $68,000 after buying an additional 7,571 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of SELLAS Life Sciences Group by 89.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after acquiring an additional 9,299 shares during the period. Opus Capital Group LLC increased its stake in shares of SELLAS Life Sciences Group by 4.2% in the 3rd quarter. Opus Capital Group LLC now owns 250,000 shares of the company’s stock valued at $403,000 after purchasing an additional 10,000 shares in the last quarter. Equitable Holdings Inc. raised its holdings in SELLAS Life Sciences Group by 58.6% in the 3rd quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock worth $44,000 after purchasing an additional 10,000 shares during the period. Finally, Axxcess Wealth Management LLC acquired a new position in SELLAS Life Sciences Group in the 3rd quarter worth about $26,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.